ecrin-mdr-crcClinical2012HypertensionMetastatic Colorectal CancerMetastatic Breast CancerColorectal NeoplasmsBreast NeoplasmsHypertensionMetastatic Colorectal CancerMetastatic Breast CancerColorectal NeoplasmsBreast NeoplasmsObservationalhttps://newmdr.ecrin.org/Study/2135628Spain10Bevacizumab Response PredictorsMetastatic Colon CancerECRIN MDRCompletedfalseEvaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal CancerThis is a multicenter, post-authorization observational with prospective follow-up (EPA-SP) study. Will be involved 137 metastatic breast cancer patients or metastatic colorectal cancer. The hypertension will be evaluated as a predictor of efficacy of bevacizumab associated with chemotherapy, in terms of progression-free survival (PFS) (Main endpoint). The duration of the study will be approximately 42 months.2012-10-152135628NCT01733628